hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06358144 id: IRB00111438 id: R01DA053209 type: NIH link: https://reporter.nih.gov/quickSearch/R01DA053209 briefTitle: Cannabis Edibles Packaging Imagery Experiment overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-07 date: 2024-07 date: 2024-04-10 date: 2024-04-10 name: Wake Forest University Health Sciences class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: The purpose of this study is to assess differences in perceptions of product appeal, harm, and subsequent willingness to try cannabis edibles products with/without packaging imagery. conditions: Cannabis Use studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will complete a 15-minute online survey, where they will be randomized to one of five conditions: four intervention conditions with a different image on the package and one without any imagery. primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 1250 type: ESTIMATED name: Packaging imagery name: No Imagery (Control) measure: Product Appeal Scoring measure: Harm Perceptions (Absolute) Scoring measure: Willingness to Try Product Scoring measure: Appeal to Children Scoring measure: Harm Perceptions (Relative) Scoring measure: Perception of Quality Scoring sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Wake Forest University Health Sciences city: Winston-Salem state: North Carolina zip: 27157 country: United States name: Alexandra Zizzi, MSPH role: CONTACT lat: 36.09986 lon: -80.24422 hasResults: False
nctId: NCT06358131 id: R.21.10.1493 briefTitle: Propofol Versus Midazolam in Sedation for Upper and Lower Gastrointestinal Endoscopy. overallStatus: RECRUITING date: 2022-01-01 date: 2024-08-01 date: 2024-08-01 date: 2024-04-10 date: 2024-04-10 name: Mansoura University class: OTHER briefSummary: There has been rapid growth in the number and complexity of gastrointestinal (GI) endoscopic procedures performed during the last decade. To ensure safe and effective upper GI endoscopy, the choice of an appropriate sedative agent is crucial. Sedation usually categorized into four stages: minimal, moderate, deep and general anesthesia. The upper gastrointestinal \[GI\] endoscopy usually performed under moderate sedation Sedation usually categorized into four stages: minimal, moderate, deep and general anesthesia. The upper gastrointestinal \[GI\] endoscopy usually performed under moderate sedation. Benzodiazepines still the most common sedative agents used for conscious sedation, either solely or in combination with opioids for upper GI endoscopy. Propofol is a hypnotic drug used for induction of anesthesia with short half-life that permits rapid patient recovery and discharge. Thus, its use is for upper GI endoscopy was adopted in many endoscopy centers. So we are going to Evaluate all adverse events related to anesthesia; in patients recruited for upper and lower endoscopy and compare between propofol and midazolam based anesthesia associated adverse events.Also we are going to Evaluate patient and endoscopist satisfaction as regarding propofol and midazolam anesthesia. conditions: Gastrointestinal Diseases studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SCREENING masking: NONE count: 656 type: ESTIMATED name: Endoscopy measure: Evaluate all adverse events related to anesthesia; in patients recruited for upper and lower endoscopy and compare between propofol and midazolam based anesthesia associated adverse events. measure: Evaluate patient and endoscopist satisfaction as regarding propofol and midazolam anesthesia. sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mansoura University status: RECRUITING city: Mansoura state: Dakhlia zip: 35516 country: Egypt name: Asmaa Gameel, MD role: CONTACT phone: 01025835429 email: asmaagameel@mans.edu.eg lat: 31.03637 lon: 31.38069 facility: MansouraU status: RECRUITING city: Mansoura country: Egypt name: Asmaa Gameel, MD role: CONTACT phone: 201025835429 email: asmaagameel165@gmail.com lat: 31.03637 lon: 31.38069 hasResults: False
nctId: NCT06358118 id: 2024-003-KY briefTitle: Buyuan-zhixiao Formula in the Treatment of Elderly Patients With Diabetes and Multiple Metabolic Disorders overallStatus: NOT_YET_RECRUITING date: 2024-05-06 date: 2025-07-01 date: 2025-07-01 date: 2024-04-10 date: 2024-04-10 name: Qing Ni class: OTHER briefSummary: The primary objective of this clinical trial is to assess the clinical efficacy and safety of the Buyuan Zhixiao Formula in treating elderly patients with diabetes and multiple metabolic disorders exhibiting symptoms of renal deficiency and blood stasis. Furthermore, this study aims to intervene in high-risk factors to prevent arteriosclerosis and to investigate the clinical efficacy of the Buyuan Zhixiao Formula in the prevention and treatment of cognitive impairments.
nctId: NCT06358105 id: id. 6457 briefTitle: Simulator Training to Improve Interventional Cardiologist Skills (STARTERS) Trial acronym: STARTERS overallStatus: NOT_YET_RECRUITING date: 2024-11-15 date: 2024-11-15 date: 2025-11-15 date: 2024-04-10 date: 2024-04-10 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: The goal of this clinical trial is to learn if simulator-based training will improve interventional cardiology fellows' skills and will improve patient outcomes.
During their first 50 procedures performed as supervised first operator, specific procedural data will be collected. conditions: Coronary Artery Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 400 type: ESTIMATED name: Simulator-based training name: Standard training measure: Mean total fluoroscopy radiation time (expressed in seconds) measure: Mean arterial cannulation time (expressed in seconds) measure: Total radiation dose (expressed in cGy*cm2) measure: Total contrast dose (expressed in ml) measure: Failure to achieve arterial cannulation (e.g.: rate of failure for each partecipant) measure: Failure to achieve right coronary cannulation (e.g.: rate of failure for each partecipant) measure: Failure to achieve left coronary cannulation (e.g.: rate of failure for each partecipant) measure: Number of catheters used measure: Any major or minor procedural and clinical complication sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Univrsitario Agostino Gemelli IRCCS city: Rome zip: 00168 country: Italy lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06358092 id: ZSSYXHNK2401 briefTitle: Two-dimensional Shear Wave Elastography for Assessment of Cirrhosis and Portal Hypertension overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-01-01 date: 2026-01-01 date: 2024-04-10 date: 2024-04-10 name: Third Affiliated Hospital, Sun Yat-Sen University class: OTHER briefSummary: Exploring and establishing new non-invasive risk stratification techniques for portal hypertension based on E imaging technology for measuring liver and spleen stiffness is an urgent need in this field of research. conditions: Cirrhosis, Liver conditions: Portal Hypertension studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 112 type: ESTIMATED name: Hepatic venous pressure gradient name: Two-Dimensional Shear Wave Elastography measure: the diagnostic performance of liver and spleen stiffness by E imaging technology for clinically significant portal hypertension measure: the diagnostic performance of microvessel imaging of hepatic microcirculation by E imaging technology for clinically significant portal hypertension measure: the difference among left, middle and right hepatic venous pressure gradient sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06358079 id: 258 briefTitle: Re-infusion of Unwashed Shed Blood During Off-pump Surgery overallStatus: RECRUITING date: 2024-03-27 date: 2026-03-30 date: 2026-03-30 date: 2024-04-10 date: 2024-04-10 name: Damascus University class: OTHER briefSummary: To assess the efficacy and side-effects of re-infusion of unwashed shed blood during off-pump coronary artery surgery using a novel cardiotomy circuit. conditions: Coronary Artery Disease conditions: Blood Transfusion Complication conditions: Cardiovascular Complication studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A prospective study involving patients undergoing off-pump coronary artery bypass surgery. Patients will be randomized to two groups; an isolated cardiotomy circuit for re-infusion of unwashed shed blood will be used in group (a) and the conventional no re-infusion technique will be used in group (b). primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Outcome assessor will be blinded to the group type when analyzing data whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Re-infusion of unwashed shed blood measure: blood transfusion requirements measure: inflammatory response measure: alveolar/arterial oxygen pressure gradients measure: cost-benefit measure: Neuro-markers measure: myocardial marker CK-MB measure: myocardial marker troponin-I measure: blood loss measure: complement response sex: ALL minimumAge: 40 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Damascus University Cardiac Surgery Hospital status: RECRUITING city: Damascus country: Syrian Arab Republic name: Mohammad Bashar Izzat, FRCS role: CONTACT phone: +963943240820 email: mbizzat@gmail.com name: Albaraa Bara, MD role: CONTACT phone: 0934206291 email: mbizzat@damascusuniversity.edu.sy lat: 33.5102 lon: 36.29128 hasResults: False
nctId: NCT06358066 id: self assembling peptides briefTitle: The Remineralization of Early Enamel Caries in Permanent Teeth overallStatus: NOT_YET_RECRUITING date: 2024-04-06 date: 2024-10-06 date: 2024-12-06 date: 2024-04-10 date: 2024-04-10 name: Tanta University class: OTHER briefSummary: Evaluate clinically the remineralizing potential of self-assembling peptide ( P11-4) fluoride plus in early enamel carious lesions of permanent anterior teeth. conditions: White Spot Lesion studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: diagnodent name: ICDAS 2 measure: measurement of mineral contents of teeth with early carious lesions among 2 arms. quantitatively using the laser fluorescence DIAGNOdent and qualitatively using ICDAS II scoring system measure: measurement of mineral contents of teeth with early carious lesions among 2 arms. quantitatively using the laser fluorescence DIAGNOdent and qualitatively using ICDAS II scoring system sex: ALL minimumAge: 10 Years maximumAge: 14 Years stdAges: CHILD hasResults: False
nctId: NCT06358053 id: CRTE7A2-2302C briefTitle: CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2027-12-31 date: 2028-04-30 date: 2024-04-10 date: 2024-04-10 name: Corregene Biotechnology Co., Ltd class: INDUSTRY briefSummary: A single center, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cells in HLA-A\*02:01+ Subjects HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine RP2D of CRTE7A2-01 TCR-T cell injection. conditions: Cervical Cancer conditions: Anal Cancer conditions: Head and Neck Cancers conditions: Other Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: CRTE7A2-01 TCR-T cell therapy measure: DLT measure: RP2D measure: cevents (SAEs). measure: Objective Response Rate (ORR) measure: Disease Control Rate (DCR) measure: Duration of Response (DOR) measure: Progression-Free Survival (PFS) measure: Overall Survival(OS) measure: Peripheral blood TCR-T cell copy number sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06358040 id: 2023-0328 briefTitle: Opioid Dispenser for Microdiscectomy/Laminectomy overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-07 date: 2024-04-10 date: 2024-04-22 name: Hospital for Special Surgery, New York class: OTHER briefSummary: The opioid crisis continues to plague the United States. While great strides have been made nationwide to decrease overprescribing, improvements are still needed to appropriately educate patients on the safe and responsible use, storage and disposal of opioids. Pain after surgery is often treated with opioid medications. Opioid medications can have side effects. Some side effects are relatively minor (constipation, nausea, vomiting), while others are more severe (sedation, abnormal breathing, etc.) and can lead to serious illness or death. Opioid pain medications when used the wrong way may also be addictive. Due to theses side effects, sometimes patients feel uncomfortable about taking these medications, and doctors prescribe them very cautiously. However, when used properly and safely, opioid pain medications are excellent pain relievers.
Addinex, a technology company, has developed a device to help patients take opioids more safely. In this study the investigators aim to enroll a total of 30 patients who undergo spine surgery. Half will be randomly assigned to receive a standard pill bottle with opioids at discharge and will download a mobile app so that they can record their daily pain scores and the number of opioids they take for two weeks after surgery. The other half will receive the new opioid dispenser filled with opioids and a mobile app that generates a passcode that opens that device only at designated times. For this group of patients, every time the patient wants to take an opioid, they need to go to the app, enter their pain score before the app generates a passcode. The investigators will be tracking all study patients' opioid use and pain scores for the two weeks after surgery, will count how many pills they have left over 14 days after their surgery during a live telehealth session, and ask patients how they liked using the device. Results from this study will help understand if the Addinex device could potentially be useful to patients in the future after surgeries as opposed to typical pill bottles. conditions: Opioid Use conditions: Pain, Postoperative conditions: Medical Device conditions: Laminectomy conditions: Diskectomy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 30 type: ESTIMATED name: Opioid-Dispensing Device name: App name: Standard Opioid Pill Bottle measure: Cumulative Opioid Consumption at Postoperative Day 14 (POD14) measure: NRS pain intensity ratings measure: Patient satisfaction with the app and with the dispensing device measure: Frequency of reported difficulties using the device measure: Frequency of reported difficulties using the app measure: Opioid prescription refill rates measure: Concordance of app data and medication left in the device or pill bottle (medication reconciliation) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital for Special Surgery city: New York state: New York zip: 10021 country: United States name: William Chan, MEng role: CONTACT phone: 917-260-4788 email: chanw@hss.edu name: Alexandra Sideris, PhD role: CONTACT phone: 212-774-2602 email: siderisa@hss.edu lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06358027 id: DokuzEU-ACC-BOtlu-01 briefTitle: Evaluation of the Effects of Different Ventilation Modes Used During Anesthesia Awakening on the Frequency of Postoperative Atelectasis overallStatus: NOT_YET_RECRUITING date: 2024-04-05 date: 2024-04-21 date: 2024-04-30 date: 2024-04-10 date: 2024-04-10 name: Dokuz Eylul University class: OTHER briefSummary: In our study, we aimed to detect atelectasis developing in patients undergoing surgery under general anesthesia using transthoracic lung ultrasonography and to investigate the effect of ventilation methods used during recovery from anesthesia on the formation of postoperative atelectasis. conditions: Atelectasis, Postoperative Pulmonary studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 278 type: ESTIMATED name: lung ultrasound measure: Modified Transthoracic Ultrasound Score sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06358001 id: 21-07 briefTitle: EchoTip AcuCore Post-Market Clinical Study overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-06-01 date: 2025-06-01 date: 2024-04-10 date: 2024-04-10 name: Cook Research Incorporated class: INDUSTRY briefSummary: The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the EchoTip AcuCore. conditions: Adenocarcinoma conditions: Neuroendocrine Tumors conditions: Hepatocellular Carcinoma conditions: Cholangiocarcinoma conditions: Malignant Lymphoma conditions: Metastasis conditions: Chronic Pancreatitis conditions: Autoimmune Pancreatitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 183 type: ESTIMATED name: EchoTip AcuCore measure: Technical Success sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06357988 id: NCI-2024-01149 id: NCI-2024-01149 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: EAY131-T type: OTHER domain: ECOG-ACRIN Cancer Research Group id: EAY131-T type: OTHER domain: CTEP id: U10CA180820 type: NIH link: https://reporter.nih.gov/quickSearch/U10CA180820 briefTitle: Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) overallStatus: ACTIVE_NOT_RECRUITING date: 2016-02-24 date: 2024-11-04 date: 2024-11-04 date: 2024-04-10 date: 2024-04-22 name: National Cancer Institute (NCI) class: NIH briefSummary: This phase II MATCH treatment trial tests how well GDC-0449 (vismodegib) works for treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that does not respond to treatment (refractory) and who have a smoothened or patched 1 genetic mutation. Vismodegib is a type of medication called a hedgehog signaling pathway antagonist and works by blocks a type of protein involved in tissue growth and repair and may block the growth of cancer cells. conditions: Advanced Lymphoma conditions: Advanced Malignant Solid Neoplasm conditions: Hematopoietic and Lymphatic System Neoplasm conditions: Refractory Lymphoma conditions: Refractory Malignant Solid Neoplasm conditions: Refractory Multiple Myeloma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: Biopsy name: Biospecimen Collection name: Echocardiography name: Radionuclide Imaging name: Vismodegib measure: Objective response rate (ORR) measure: Overall survival (OS) measure: 6-month progression-free survival (PFS) rate measure: Progression free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ECOG-ACRIN Cancer Research Group city: Philadelphia state: Pennsylvania zip: 19103 country: United States lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06357975 id: NCI-2024-01126 id: NCI-2024-01126 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: EAY131-C1 type: OTHER domain: ECOG-ACRIN Cancer Research Group id: EAY131-C1 type: OTHER domain: CTEP id: U10CA180820 type: NIH link: https://reporter.nih.gov/quickSearch/U10CA180820 briefTitle: Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) overallStatus: ACTIVE_NOT_RECRUITING date: 2016-05-30 date: 2024-11-15 date: 2024-11-15 date: 2024-04-10 date: 2024-04-22 name: National Cancer Institute (NCI) class: NIH briefSummary: This phase II MATCH treatment trial tests how well crizotinib works in treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that does not respond to treatment (refractory) and who have MET gene amplification. Crizotinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow. conditions: Advanced Lymphoma conditions: Advanced Malignant Solid Neoplasm conditions: Refractory Lymphoma conditions: Refractory Malignant Solid Neoplasm conditions: Refractory Multiple Myeloma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Biopsy name: Biospecimen Collection name: Crizotinib name: Radiologic Examination measure: Objective response rate (ORR) measure: Overall survival (OS) measure: 6-month progression-free survival (PFS) rate measure: Progression free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ECOG-ACRIN Cancer Research Group city: Philadelphia state: Pennsylvania zip: 19103 country: United States lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06357962 id: CSAPG-40 briefTitle: Semi-permanent Acupuncture Effect on Cervical Ripening overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2025-09 date: 2025-10 date: 2024-04-10 date: 2024-04-12 name: Consorci Sanitari de l'Alt Penedès i Garraf class: OTHER briefSummary: Cervical ripening is a medical treatment that can cause physical or emotional discomfort in pregnant women and is not without risks. This is a pilot study to assess feasibility and calculate the number of participants necessary for a complete clinical trial. The aim is to evaluate whether acupuncture can reduce the need for treatment (cervical ripening) in pregnant women at low or intermediate risk. Participants will be divided into two groups: one group will receive acupuncture, and the other will receive a simulated treatment of acupuncture. conditions: Pregnancy Complications studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 30 type: ESTIMATED name: Semi-permanent acupuncture name: Sham of semi-permanent acupuncture measure: Pharmacological induction measure: Change on score of Bishop scale measure: Onset of spontaneous labor measure: Duration of induction period Duration of the induction period Duration of the induction period Duration of the induction period measure: Duration of labor period measure: Satisfaction of pregnants sex: FEMALE maximumAge: 40 Years stdAges: CHILD stdAges: ADULT facility: Consorci Sanitari Alt Penedes i Garraf city: Vilafranca Del Penedès state: Barcelona zip: 08720 country: Spain name: Gloria Villena role: CONTACT phone: +34 938180440 phoneExt: 43197 email: gvillena@csapg.cat name: Noemí Casaponsa role: CONTACT phone: +34 938960025 phoneExt: 43197 email: recerca@csapg.cat lat: 41.34618 lon: 1.69713 hasResults: False